Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ralf Lorenz"'
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Autor:
Hanna Huebner, Lothar Häberle, Volkmar Müller, Iris Schrader, Ralf Lorenz, Helmut Forstbauer, Visnja Fink, Fabienne Schochter, Inga Bekes, Sven Mahner, Julia Jückstock, Naiba Nabieva, Andreas Schneeweiss, Hans Tesch, Sara Y. Brucker, Jens-Uwe Blohmer, Tanja N. Fehm, Georg Heinrich, Mahdi Rezai, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack
Publikováno v:
Cancers, Vol 14, Iss 7, p 1721 (2022)
Soluble MUC1 has been discussed as a biomarker for predicting prognosis, treatment efficacy, and monitoring disease activity in breast cancer (BC) patients. Most studies in adjuvant settings have used preoperative assessment. This study, part of the
Externí odkaz:
https://doaj.org/article/d83c2b6f90764c77a58c56a3072e7728
Autor:
A von der Assen, F Marmé, Michael Untch, Toralf Reimer, Helmut Forstbauer, R.J.C. Mahlberg, Bruno Valentin Sinn, Mattea Reinisch, Sabine Schmatloch, G. von Minckwitz, Nicole Burchardi, Elmar Stickeler, Oliver Tomé, S. Loibl, N Klutinus, Sabine Seiler, Ralf Lorenz, Wolfgang Janni, Martina Schmidt, Volker Möbus
Publikováno v:
Cancer Research. 78:P5-20
Background A new subcutaneous (s.c.) formulation of trastuzumab became available in 2013 based on equivalent efficacy, pharmacokinetic (PK) profile and safety with the standard intravenous (i.v.) administration, where the s.c. trastuzumab was adminis
Autor:
Julian Koch, Wolfgang Janni, M. W. Beckmann, Bernadette Jäger, Lennard Schröder, Ralf Lorenz, Peter A. Fasching, Christoph Scholz, Tobias Weissenbacher, Brigitte Rack, Mahdi Rezai, Andreas Schneeweiss, Harald Sommer, Twp Friedl, A Schramm, Lothar Häberle
Introduction: This paper aims to evaluate the toxicity profile of additive gemcitabine to adjuvant taxane-based chemotherapy in breast cancer patients. Methods: Patients enrolled in this open-label randomized controlled Phase III study were treated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9975bdd26328c60e7dc4d0694342ae81
https://europepmc.org/articles/PMC4873296/
https://europepmc.org/articles/PMC4873296/
Autor:
K. Pantel, Thomas Zwingers, Ralf Lorenz, Brigitte Rack, Ulrich Andergassen, Wolfgang Janni, Hans Tesch, Julia Neugebauer, Harald Sommer, Helmut Forstbauer, Mahdi Rezai, Philip Hepp, Matthias W. Beckmann, Andreas Schneeweiss, Julia Kathrin Jueckstock, Klaus Friese, Werner Lichtenegger
Publikováno v:
Journal of Clinical Oncology. 29:1033-1033
1033 Background: The prognostic significance of CTC in primary breast cancer has been demonstrated for 2,026 patients (pts) of the German SUCCESS-study (Rack et al, in press). In this analysis the prognostic relevance of CTC in peripheral blood at pr
Autor:
Wolfgang Janni, Werner Lichtenegger, Achim Schneider, Ralf Lorenz, D. Chatsiproios, Mahdi Rezai, EM Genss, Andreas Schneeweiss, M. W. Beckmann, Brigitte Rack, Klaus Friese, Jörn Hilfrich, Harald Sommer
Publikováno v:
Cancer Research. 69:4108
Abstract #4108 Background: Taxane containing regimens have been established as standard of care for node-positive primary breast cancer patients and have shown superiority to mere anthracycline containing regimens. The SUCCESS-trial evaluates, whethe
Autor:
Wolfgang Janni, Ralf Lorenz, K. Pantel, Jörn Hilfrich, Matthias W. Beckmann, Brigitte Rack, Christian Schindlbeck, Andreas Schneeweiss, Werner Lichtenegger, Harald Sommer
Publikováno v:
Journal of Clinical Oncology. 26:503-503
503 Background: The prognostic significance of CTCs in metastatic breast cancer has been demonstrated. If the presence of CTCs in early breast cancer would also predict an increased risk for relapse, this method might be used as an early marker for t